Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 936 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Revance Therapeutics Inc | RVNC | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.14 | 3.83% | 3.80 | 08:47:57 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.66 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 8 | 936 | - | 3.61 - 37.98 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:47:57 | formt | 200 | $ 3.80 | USD |
Revance Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 322.86M | 88.21M | - | 234.04M | -323.99M | -3.67 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Revance Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RVNC Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.87 | 3.90 | 3.61 | 3.72 | 1,759,332 | -0.07 | -1.81% |
| 1 Month | 4.78 | 5.03 | 3.61 | 4.21 | 1,581,641 | -0.98 | -20.50% |
| 3 Months | 5.45 | 7.56 | 3.61 | 5.36 | 1,824,604 | -1.65 | -30.28% |
| 6 Months | 8.49 | 9.745 | 3.61 | 6.32 | 1,720,106 | -4.69 | -55.24% |
| 1 Year | 32.11 | 37.98 | 3.61 | 13.31 | 1,678,278 | -28.31 | -88.17% |
| 3 Years | 29.35 | 37.98 | 3.61 | 18.48 | 1,214,548 | -25.55 | -87.05% |
| 5 Years | 13.59 | 37.98 | 3.61 | 19.10 | 946,405 | -9.79 | -72.04% |
Revance Therapeutics Description
| Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in the research and development of aesthetic and therapeutic products. |
